Image Image Image Image Image Image Image Image Image Image
Access
Up

Up

Results for: amd

Dr Jordi Monés MD, PhD

10/04/2013

…erimental photodynamic therapy at the MEEI and was afterwards actively engaged in the early Trials for exudative AMD, the TAP and VIP studies. At his return to Barcelona, after Harvard University and Tecnológico de Monterrey, he pioneered the use and development of novel AMD imaging techniques, particularly indocyanine angiography, and related laser therapies, such as feeder vessel treatment. Subsequently he has been principal investigator and ex…

Dr Jordi Monés MD, PhD

04/04/2013

…erimental photodynamic therapy at the MEEI and was afterwards actively engaged in the early Trials for exudative AMD, the TAP and VIP studies. At his return to Barcelona, after Harvard University and Tecnológico de Monterrey, he pioneered the use and development of novel AMD imaging techniques, particularly indocyanine angiography, and related laser therapies, such as feeder vessel treatment. Subsequently he has been principal investigator and ex…

A clinical trial conducted by the Institut aims to show the efficacy and safety of Lampalizumab in intravitreal injections for the atrophic form of AMD

30/10/2015

Lampalizumab is the first therapy to show significant efficacy in halting the progression of AMD in certain patients. The research forms part of the programme of international clinical trials conducted by the Institut de la Màcula. The trial aims to respond to the problems of patients with geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). The Institut de la Màcula is the first centre in Europe to be accredited to co…

Exudative or wet AMD

22/03/2013

What is AMD?   Age-related macular degeneration, the gradual degeneration of the macula, is the primary cause of sight loss in the western world in patients aged over fifty. More than 25 million people currently suffer from this illness in the world, with an additional 500,000 every year, approximately. There are many subtypes of AMD but basically two broad forms: wet or exudative and dry or atrophic. What are the effects of wet AMD?   The AMD

The Institut announces study using postbiotics in AMD patients

16/10/2020

…etic predisposition only partially responds to the incidence, and especially, to the progression and severity of AMD. We know that epigenetic factors are crucial in determining the progression and severity of the disease. One of the best ways of modulating these factors is to focus on the microbiome. A good approach is by using postbiotics, a functional food that could modulate the epigenome of patients with AMD, macular atrophy and choroidal neo…

The Barcelona Macula Foundation and the Institut de la Màcula study the relationship between AMD and the intestinal and oral microbiome

21/01/2020

…degeneration (AMD). The main aim is to characterise the microbiome through the RNA 16S sequencing of those with AMD and compare it with the microbiome of healthy patients, and also to discover differences between different AMD phenotypes. This means that we could identify whether a single microbial composition can be associated with a specific phenotype. Given the premise that the microbiome is potentially modifiable, this study could open new a…

Dry or atrophic AMD

22/03/2013

What is AMD?   Age-related macular degeneration (AMD) is the primary cause of sight loss in the western world in patients aged over fifty. More than 25 million people currently suffer from this illness in the world, with an additional 500,000 every year, approximately. There are many subtypes of AMD but basically two broad forms: wet or exudative and dry or atrophic. Dry AMD makes up 85 % of all cases of age-related macular degeneration. Althou…

The Institut de la Màcula sees in 2020 with a new clinical trial for geographic atrophy secondary to AMD

17/02/2020

…tic and clinical lines of evidence in humans indicate that the complement system plays a role in the etiology of AMD. Complement protein C3 (which has a pro-inflammatory action), the membrane attack complex and complement factor H are present in drusen and in basal laminar deposits of patients with AMD. APL-2 is a drug for intravitreal use that blocks the action of C3, its main action being anti-inflammatory. The results of previous studies suppo…

The Institut will present at EURETINA the results of the phase III trial OPH1002/3 with Fovista for exudative AMD

20/07/2017

…h factor (PDGF) inhibitor in combination with a vascular endothelial growth factor (VEGF) inhibitor in exudative AMD. The use of this combined therapy might improve monotherapy with anti-VEGF that already exists for exudative AMD. Due to the capacity of anti-PDGF to induce the detachment of pericytes, in conjunction with the action of anti-VEGF, this might be more effective in halting the formation of new blood vessels and, with it, the progressi…

“We form part of a knowledge hub, connected to the world’s leading institutions”

01/06/2017

…ses that remain incurable today». When you created the Institut de la Màcula 10 years ago the treatments for wet AMD had barely begun. Have we now tamed this pathology? We have experienced a revolution: remember that wet AMD was  — is, if it is not treated — a devastating pathology. To stop it we need two things. First, a good diagnosis. To address it effectively we have to know what lies ahead. If you don’t know your opponent he can beat you in…

Last modified: 29 November, 2021 - 13:07